WuXi STA, a powerhouse in the global Contract Research, Development, and Manufacturing Organization (CRDMO) sector, has recently launched a high potency, fully automated sterile injectable manufacturing line. Set up at the company’s Wuxi City site, this line represents a robust response to the growing demands of the high potency pharmaceuticals market.
The most remarkable feature of this line is its well-thought-out design. By incorporating fully enclosed isolation systems and automated filling machines, WuXi STA has managed to significantly reduce human intervention, thereby lowering the risk of cross-contamination. Additionally, an independent air conditioning system and a bag-in bag-out (BIBO) exhaust air purification system have been included, ensuring the safety of operators and the environment alike.
In line with its future-forward approach, WuXi STA plans to install two more injectable manufacturing lines at the Wuxi City site by 2024. This strategic move is in sync with the vision articulated by Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, who is committed to bolstering WuXi STA’s CRDMO platform capabilities and making a positive impact on global patient care.